1. Home
  2. ELVN vs NVEE Comparison

ELVN vs NVEE Comparison

Compare ELVN & NVEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • NVEE
  • Stock Information
  • Founded
  • ELVN 2016
  • NVEE 1949
  • Country
  • ELVN United States
  • NVEE United States
  • Employees
  • ELVN N/A
  • NVEE N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • NVEE Other Consumer Services
  • Sector
  • ELVN Health Care
  • NVEE Consumer Discretionary
  • Exchange
  • ELVN Nasdaq
  • NVEE Nasdaq
  • Market Cap
  • ELVN 1.1B
  • NVEE 1.2B
  • IPO Year
  • ELVN 2020
  • NVEE 2013
  • Fundamental
  • Price
  • ELVN $21.86
  • NVEE $18.99
  • Analyst Decision
  • ELVN Strong Buy
  • NVEE Buy
  • Analyst Count
  • ELVN 5
  • NVEE 2
  • Target Price
  • ELVN $37.80
  • NVEE $28.75
  • AVG Volume (30 Days)
  • ELVN 220.2K
  • NVEE 421.5K
  • Earning Date
  • ELVN 03-13-2025
  • NVEE 02-20-2025
  • Dividend Yield
  • ELVN N/A
  • NVEE N/A
  • EPS Growth
  • ELVN N/A
  • NVEE N/A
  • EPS
  • ELVN N/A
  • NVEE 0.54
  • Revenue
  • ELVN N/A
  • NVEE $914,188,000.00
  • Revenue This Year
  • ELVN N/A
  • NVEE $11.42
  • Revenue Next Year
  • ELVN N/A
  • NVEE $5.61
  • P/E Ratio
  • ELVN N/A
  • NVEE $35.10
  • Revenue Growth
  • ELVN N/A
  • NVEE 9.86
  • 52 Week Low
  • ELVN $10.90
  • NVEE $17.92
  • 52 Week High
  • ELVN $30.03
  • NVEE $28.29
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 44.27
  • NVEE 47.17
  • Support Level
  • ELVN $21.45
  • NVEE $18.73
  • Resistance Level
  • ELVN $22.82
  • NVEE $19.02
  • Average True Range (ATR)
  • ELVN 1.55
  • NVEE 0.69
  • MACD
  • ELVN 0.00
  • NVEE 0.17
  • Stochastic Oscillator
  • ELVN 32.63
  • NVEE 55.53

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About NVEE NV5 Global Inc.

NV5 Global Inc is a provider of technology, conformity assessment, and consulting solutions to public and private sector clients in the infrastructure, utility services, construction, real estate, environmental, and geospatial markets, operating nationwide and abroad. The Company's clients include the U.S. Federal, state and local governments, and the private sector. The operating business segments are Infrastructure, Building, Technology & Sciences, and Geospatial Solutions. The maximum revenue derives from the infrastructure segment.

Share on Social Networks: